Growth Hormone & Performance

GHRP-1

GHRP-1 is one of the first synthetic growth hormone-releasing peptides, and it works through a different door from growth hormone-releasing hormone: the ghrelin receptor, which is why the two amplify each other when given together and why the whole class exists. It has largely been superseded by later members of its family. Its human record is a single randomised study from 1998 in which a 100-microgram intravenous bolus went to ten women and 58 new mothers, with blood growth hormone read at twenty minutes — one timepoint, one hormone. The one registered trial of it, in dialysis patients, closed in 2007 for lack of enrolment, with three people signed up.

Last updated 12 August 2026

Studied forGrowth hormone release research · IGF-1 response research · Secretagogue pharmacology context

Evidence on file1 randomised human trial · 1 animal study · 1 in-vitro study · 1 citation not yet graded

Strongest sourcePostpartum hyperprolactinemia and hyporesponsiveness of growth hormone (GH) to GH-releasing peptide (randomised human trial)

Mechanism

Agonist at the growth hormone secretagogue receptor GHS-R1a; acts synergistically with GHRH and opposes somatostatin.

Reported effects

What sources associate with this compound. Reported categories, not outcomes we have graded — each would need its own citation and rung.

Growth hormone release research
IGF-1 response research
Secretagogue pharmacology context

Dosing on file unverified

IV: 1 mcg/kg bolus; IV: 0.05-2.5 mcg/kg infusion; SC: single injection (NCT00381602)

Carried from a source that labels it unverified, and reproduced with that label attached. A record of what is reported, not a recommendation. No citation on this page establishes it.

Half-life, storage & sport

Elimination half-life: not on file — No pharmacokinetic value for GHRP-1 has been published. It has never been an approved medicine, so there is no label, and of the 41 PubMed records naming it none states a half-life or a clearance. The three returned by a pharmacokinetics search report growth hormone responses after a bolus, which is the duration of the effect and not the half-life of the peptide.

Literature on file 4

human RCT
Postpartum hyperprolactinemia and hyporesponsiveness of growth hormone (GH) to GH-releasing peptide graded on: names a randomised controlled trial — the indexed publication type — “Randomized Controlled”
in vitro
Growth hormone isoforms in newborns and postpartum women graded on: an in-vitro system — read from the indexed abstract — “assay”
animal in vivo
In vivo effects of the GH-releasing heptapeptide GHRP-1 in lambs graded on: an animal model — “lambs”

Not graded

1 citation whose study design could not be read from the title. Left ungraded rather than guessed at.

not graded
NCT00381602: A Phase II, Randomized, Cross-Over, Vehicle-Controlled, Double-Blind, Multicenter Study of the Safety, Pharmacodynamics, and Preliminary Efficacy of GHRP-1/AG in Subjects With ESRD on Hemodialysis graded on: NCT00381602 is terminated and has posted no results - a registration, not a reported outcome — “NCT00381602”

Identity

Space-filling 3D model of GHRP-1, carbon grey, nitrogen blue, oxygen red — Built from the SMILES on this record — the atoms and bonds are exact. The shape is **one computed low-energy pose**, not a measured structure: a flexible peptide in solution has no single conformation, and where the SMILES leaves a stereocentre undefined the pose commits to one arbitrarily. The skeletal formula below claims connectivity and nothing more, which is what we actually know.

2D chemical structure of GHRP-1 — Built from the SMILES on this record — the atoms and bonds are exact. The shape is **one computed low-energy pose**, not a measured structure: a flexible peptide in solution has no single conformation, and where the SMILES leaves a stereocentre undefined the pose commits to one arbitrarily. The skeletal formula below claims connectivity and nothing more, which is what we actually know.

Molecular weight: 955.1
Molecular formula: C51H62N12O7
CAS number: 141925-59-9
PubChem CID: 10350910
InChI key: NWQWNCILOXTTHF-HLCSKTDOSA-N
Sequence: AHXAWFK
SMILES: C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@H](CC2=CC3=CC=CC=C3C=C2)C(=O)N[C@@H](C)C(=O)N[C@@H](CC4=CNC5=CC=CC=C54)C(=O)N[C@H](CC6=CC=CC=C6)C(=O)N[C@@H](CCCCN)C(=O)N)N
InChI: InChI=1S/C51H62N12O7/c1-30(53)46(65)60-44(26-37-28-55-29-57-37)51(70)63-42(24-33-19-20-34-14-6-7-15-35(34)22-33)48(67)58-31(2)47(66)61-43(25-36-27-56-39-17-9-8-16-38(36)39)50(69)62-41(23-32-12-4-3-5-13-32)49(68)59-40(45(54)64)18-10-11-21-52/h3-9,12-17,19-20,22,27-31,40-44,56H,10-11,18,21,23-26,52-53H2,1-2H3,(H2,54,64)(H,55,57)(H,58,67)(H,59,68)(H,60,65)(H,61,66)(H,62,69)(H,63,70)/t30-,31-,40-,41+,42+,43-,44-/m0/s1

Notes unverified prose

Human studies: 1 mcg/kg IV; 0.05-2.5 mcg/kg IV; NCT00381602 (SC); Human IV studies: 1 mcg/kg bolus; NCT00381602

Not on file 4

All 8 tracked fields hold a value on this record. 4 further absences are named below. A blank field is a bug; a named absence is a finding.

half-lifeno pharmacokinetic study in any species on file
clinical outcomethe human studies on file measured GH secretion after a single intravenous bolus; no study on file measured a clinical outcome
repeat dose safetyNCT00381602 was terminated at 3 enrolled subjects and posted no results; no repeat-dose human safety record on file
esrd haemodialysis evidencethe only registered trial in this population reported nothing

Each field links to every other record missing the same thing. The full ledger holds 765 gaps across 163 records.

At a glance

Strongest rung: human RCT
Citations: 4
Regulatory: In or past clinical trials (verified)
Route: Intravenous / Subcutaneous
Declared gaps: 4

Running this

Growth hormone axis

How the class is run, with the source of every schedule beside it.

Citations by rung

Strongest wins, never an average.